Summit Therapeutics Share Discussion Threads

[hugus maximus] 04/8/2016 10:03

Thanks Algernon2 ... surely Bamboo are years behind Summit's work? Interesting to see that they are entering both PI and PII trials at the same time? That's a first for me.

[algernon2] 04/8/2016 09:51

The below link was posted by Trovax on the OXB Board but mentions DMD in the third paragraph so is interesting for Summ also.

"...The focus of the deal is BMB-D001, Bamboo’s gene therapy for Duchenne muscular dystrophy, which is scheduled to enter a phase I/II trial by the end of the year. BMB-D001 is a recombinant adeno-associated viral (rhAAV) vector that delivers a shortened but functional copy of the dystrophin gene."

[hugus maximus] 04/8/2016 09:21

Thanks Chris .... that web address should have "tt" inserted where ADVFN interprets with "xx"

[hugus maximus] 03/8/2016 20:05

Sarepta are hanging on like grim death to anything positive ... shares went up 5% today after a government note said they're recruiting patients for Phase III trials:-

hxxps://www.thestreet.com/story/13663409/1/sarepta-srpt-stock-advances-on-phase-iii-trial-recruitment.html?puc=yahoo&;cm_ven=YAHOO&yptr=yahoo

Analyst Note : - "We, however, remain skeptical of the ability to draw positive implications from this development and continue to believe the deck is stacked against Sarepta Therapeutics,"

Edit : Perhaps the once thought impossible idea of Saraepta getting FDA approval can be compared to the once impossible thought of Trump being President?! Are we about to see pigs entering United States air space?

[chrisatrdg] 03/8/2016 10:26

Per Free-Money today:
'RE: SMT19969 Clinical trial
Thanks Gerry,

That seems to fit in with their timeline of having the results out in Q3.
It's a 10 day dosing and 30 day recurrence window I seem to remember.
So I would expect the testing will be all complete within the month if not already. They take as long as a piece of string to collate the results and produce the report though so it's anyone's guess when we'll see the results.

I'm told the deal discussions are not waiting for these results but if good and in time, they will certainly add some significant weight to the talks, especially considering the pricing structure of Fidaxomicin.
GLA'

[chrisatrdg] 03/8/2016 08:31

Per gmcc from the other board:

'SMT19969 Clinical trial
Good morning

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

FYI : Note “This study is ongoing, but not recruiting participants” new update 1st August

Sites in UK, USA & Czech Republic



Edit chrisatrdg - This is some news today.

[chrisatrdg] 03/8/2016 07:22

But not for long hopefully !!!

[sorrento06] 02/8/2016 14:51

Most boring share on LSE

[waterloo01] 29/7/2016 19:17

FD, timely reminder. I hope 'partners' have that in mind when they submit offers and we see that translated into a deal that lives up the 'transformation' we have long waited (and funded).

It's getting close to put up or shut up time. (not that the market cap reflects it!)

[chrisatrdg] 29/7/2016 18:27

Does not bode well for Summit if -----.

Biotech IPOs sink this summer--10 of last 12 are underwater

[waterloo01] 29/7/2016 17:56

Edit: It was Surotomycin that had a bad result reported at ASM in June.

Conclusions: Surotomycin demonstrated non-inferiority to vancomycin for primary endpoint but neither key secondary superiority endpoints were met. Surotomycin was generally well tolerated



The Seres one makes a 2nd failure in the field. Can't harm our deal making at all, as one of the 'sticking' points will be the competitive treatments in the pipeline

[chrisatrdg] 29/7/2016 15:13

per gmcc from the other board showing link for above:

Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection

- Primary efficacy endpoint was not achieved -

[solomon] 29/7/2016 13:54

Is this a better time to buy than the last good time to buy?

[joe shone] 29/7/2016 13:38

re Seres,the primary endpoint was not achieved in C DIF trials,shares are plummeting.good time to buy some summ i would suggest.gl,joe

[waterloo01] 29/7/2016 11:10

The inaugural ASM Microbe 2016 conference included several presentations on emerging treatment approaches for CDI. Richard J. Vickers, PhD, of Summit, presented additional efficacy and safety data from the phase 2 CoDIFy trial that compared the narrow-spectrum antibiotic ridinilazole with vancomycin in 100 patients. Ridinilazole treatment conferred a sustained clinical response rate of 66.7% compared with 42.4% for vancomycin (difference 21.1%; 90% CI, 3.1-39.1), and a recurrence rate of 14.3% vs. 34.8% for vancomycin. A subgroup analysis favored ridinilazole over vancomycin even in groups at higher risk for rCDI, such as patients older than 75 years, those with severe disease and those with previous CDI episodes. There were no clinically important differences between ridinilazole and vancomycin in adverse or serious adverse events. Furthermore, as reported in a late-breaking poster, ridinilazole did not appear to induce any significant changes in the native microbiome.

[luminoso] 28/7/2016 18:27

Thanks, chris.

[chrisatrdg] 28/7/2016 15:37

Ralf Rosskamp, MD from Summit presents at PPMD's 2016 Connect Conference on June 27, 2016.

Summit Therapeutics Retweeted

Parent Project MD ‏@ParentProjectMD 16m16 minutes ago

Trials in Duchenne - Summit [PPMD's 2016 Connect Conference]:

via @YouTube

Above now on Summit website.

[luminoso] 28/7/2016 12:06

Well, there's the start of the rebound. Some cynics might say they left a little time for a few other buys to trickle in not wanting it to look too indecent. I could not possibly comment.

[freedosh] 28/7/2016 09:47

If those were buys the share price would have rebounded. Rollover Plus? IMO

[luminoso] 28/7/2016 09:17

I would love it to be a director buy, but I guess if they are talking to possible JV partners on C.Diff, and I hope they still are ! , they would not be able to buy shares.

[waterloo01] 28/7/2016 09:07

Finally a director buy? Probably not. I noticed that. They did a 100 trade at 95.5p quickly followed by the buy.

[waterloo01] 27/7/2016 11:10

Have to say if they had managed to keep to the timetable re DMD phase 2, we would have had the first read-out in September. If they had shown some meaningful improvements, we would have had funds jumping all over us to fund Utrophin up-regulation. As it stands, they won't have much data before they need funds so it all hangs on the deal re Rid'nazole.

If the deal has say under $25m upfront, it might be enough to see us through to 2nd half 2017, when we should have some meaningful data on DMD.

Naturally I'm hoping/expecting a much better upfront as it's about time SUMM started to deliver some returns.